ReviewJournal of clinical medicine2022
Advances in the Treatment of Giant Cell Arteritis.
Review in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 41 citations in OpenAlex.
- Small-Molecule Strategies for Polymyalgia Rheumatica and Giant Cell Arteritis in Older Adults.Molecules (Basel, Switzerland) · 2026Review
- Methylprednisolone pulses are associated with faster remission in Giant Cell Arteritis: a multicentre inception cohort study.Arthritis research & therapy · 2026Observational
- Treatment and evolution of 134 patients with aortitis and periaortitis: experience of a third-level university hospital.Internal and emergency medicine · 2026Observational
- Increased expression of Toll-like receptors and associated alarmins in temporal arteries of patients with giant cell arteritis.Molecular medicine (Cambridge, Mass.) · 2025Article
- Monocytes/Macrophages in Giant Cell Arteritis-Polymyalgia Rheumatica Spectrum Disease.Aging and disease · 2025Review
- Giant Cell Arteritis With Atypical Features: Acute Vision Loss and Marked Eosinophilia Mimicking Systemic Vasculitis.Cureus · 2025Article
- Article
- Birdshot Chorioretinopathy in a Patient on Tocilizumab for the Treatment of Giant Cell Arteritis.Case reports in ophthalmological medicine · 2025Article
- Faster steroid-free remission with tocilizumab compared to methotrexate in giant cell arteritis: a real-life experience in two reference centres.Internal and emergency medicine · 2024Article
- 18F-FDG-PET/CT Scan for Detection of Large Vessel Involvement in Giant Cell Arteritis: Arteser Spanish Registry.Journal of clinical medicine · 2024Article
- Review
- Association of clinical, imaging and laboratory parameters with adverse effects of glucocorticoid therapy in patients with giant cell arteritis.Frontiers in medicine · 2024Article
- Role and potential ofFrontiers in medicine · 2024Review
- Safety and Efficacy of Long-Term Tocilizumab in a Cohort of Patients with Giant Cell Arteritis: An Italian Monocentric Retrospective Study.Biologics : targets & therapy · 2024Article
- Review
- Tocilizumab Vs Methotrexate in a Cohort of Patients Affected by Active GCA: A Comparative Clinical and Ultrasonographic Study.Biologics : targets & therapy · 2023Article
- Article
- Comment on: Benchmarking tocilizumab use for giant cell arteritis.Rheumatology advances in practice · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
Abstract
Giant cell arteritis (GCA) is the most common vasculitis among elderly people. The clinical spectrum of the disease is heterogeneous, with a classic/cranial phenotype, and another extracranial or large vessel phenotype as the two more characteristic patterns. Permanent visual loss is the main short-term complication. Glucocorticoids (GC) remain the cornerstone of treatment. However, the percentage of relapses with GC alone is high, and the rate of adverse events affects more than 80% of patients, so it is necessary to have alternative therapeutic options, especially in patients with worse prognostic factors or high comorbidity. MTX is the only DMARD that has shown to reduce the cumulative dose of GC, while tocilizumab is the first biologic agent approved due to its ability to decrease the relapse rate and lower the cumulative GC doses. However, apart from the IL-6 pathway, there are other pro-inflammatory cytokines and growth factors involved in the typical intima hyperplasia and vascular remodeling of GCA. Among them, the more promising targets in GCA treatment are the IL12/IL23 axis antagonists, IL17 inhibitors, modulators of T lymphocytes, and inhibitors of either the JAK/STAT pathway, the granulocyte-macrophage colony-stimulating factor, or the endothelin, all of which are updated in this review.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.